Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd (ENTX) is a clinical-stage biopharmaceutical company pioneering oral peptide therapies for chronic conditions like osteoporosis and hypoparathyroidism. This page provides investors and industry professionals with timely updates on the company’s clinical trials, regulatory milestones, and strategic initiatives.
Access the latest press releases and news about Entera Bio’s proprietary drug delivery platform, which aims to transform treatment paradigms by replacing injectable therapies with oral alternatives. Track developments across their pipeline, including phase advancements for lead candidates and collaborations advancing oral macromolecule research.
Key updates include progress on EB613 for bone health, EB612 for hormone regulation, and innovations in peptide absorption technology. Bookmark this page to stay informed about financial disclosures, partnership announcements, and scientific breakthroughs directly from the source.
Entera Bio Ltd. (NASDAQ: ENTX) has announced the appointment of Dr. Steven R. Goldstein to its Clinical and Scientific Advisory Board. Dr. Goldstein, a prominent figure in menopause research, will play a crucial role in the development of Entera's EB613 program. This innovative therapy aims to provide an oral treatment for post-menopausal osteoporosis, addressing a significant medical need in women's health. The company emphasizes the importance of actively managing bone health for post-menopausal women, especially given the high mortality rates associated with untreated osteoporosis. Entera’s EB613 is designed to be the first oral osteoanabolic therapy, offering hope for improved treatment outcomes.
Entera Bio Ltd. (NASDAQ: ENTX) announced feedback from its Type D Meeting with the FDA regarding its EB613 program for treating postmenopausal osteoporosis. The FDA accepted the use of Total Hip Bone Mineral Density (BMD) as a primary endpoint in a proposed 24-month placebo-controlled Phase 3 trial. They also affirmed the proposed pharmacokinetic study design aligns with FDA expectations. Entera CEO expressed gratitude for the FDA's support, emphasizing the potential of EB613 as the first oral osteoanabolic treatment for millions of women. The company is preparing to advance its EB612 program for hypoparathyroidism into Phase 2 by 2024.
Entera Bio Ltd. (NASDAQ: ENTX) reported its 2022 financial results, indicating significant corporate progress, particularly with its EB613 program aimed at osteoporosis treatment. Total revenues decreased to $134,000 from $571,000 in 2021, resulting in a net loss of $13.1 million, or $0.45 per share. R&D expenses also dropped to $5.8 million, while G&A expenses rose to $7.3 million due to increased compensation. Entera anticipates having sufficient cash of $12.3 million to support operations through Q3 2024 and plans to advance its EB612 program for hypoparathyroidism into Phase 2 in 2024.
Entera Bio Ltd. (NASDAQ: ENTX) announced on March 23, 2023, that it has regained compliance with NASDAQ's minimum bid price requirement. This follows a previous notification from NASDAQ on November 21, 2022, when the company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Entera's ordinary shares have closed at $1.00 or higher for the last 14 consecutive business days, thus resolving the compliance issue. The company remains listed on The NASDAQ Capital Market and adheres to all applicable listing standards.
FAQ
What is the current stock price of Entera Bio (ENTX)?
What is the market cap of Entera Bio (ENTX)?
